CORYNOXEINE

Possibly Marketed Outside US

First approved in 2021

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H26N2O4
Molecular Weight	382.4528
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO\C=C(/[C@H]1C[C@@H]2N(CC[C@]23C(=O)NC4=CC=CC=C34)C[C@@H]1C=C)C(=O)OC

InChI

InChIKey=MUVGVMUWMAGNSY-KAXDATADSA-N

InChI=1S/C22H26N2O4/c1-4-14-12-24-10-9-22(17-7-5-6-8-18(17)23-21(22)26)19(24)11-15(14)16(13-27-2)20(25)28-3/h4-8,13-15,19H,1,9-12H2,2-3H3,(H,23,26)/b16-13+/t14-,15-,19-,22+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H26N2O4
Molecular Weight	382.4528
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18981576
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24522518

Corynoxeine is a compound isolated from Uncaria rhynchophylla, a traditional Chinese herb that has been applied to the treatment of convulsive disorders in China. Corynoxeine was found to inhibit PDGF-BB-induced activation of ERK1/2 and vascular smooth muscle cells proliferation. Corynoxeine found to induce autophagy in different neuronal cell lines, including N2a and SHSY-5Y cells and may have potential application for the prevention or treatment of Parkinson's disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mitogen-activated protein kinase; ERK1/ERK2 4 Target ID: CHEMBL1907606 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18981576	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24522518	Preventing		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.	2014-06	24522518
The blood-brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansan.	2011-07	21442303
Corynoxeine isolated from the hook of Uncaria rhynchophylla inhibits rat aortic vascular smooth muscle cell proliferation through the blocking of extracellular signal regulated kinase 1/2 phosphorylation.	2008-11	18981576

Patents

Sample Use Guides

In Vivo Use Guide

In a rat PK study, Yokukansan (a traditional Japanese medicine, containing corynoxeine) was administered orally at 1 or 4 g/kg.

Route of Administration: Oral

In Vitro Use Guide

Vascular smooth muscle cells (VSMCs) were seeded in 12-well culture plates at 5x104 cells/ml and cultured in DMEM with 10% FBS at 37 °C for 24 h. Under these conditions, the cells reached ca. 70% confluence. VSMCs were pre-cultured in serum-free medium in the presence and absence of corynoxeine (5 - 50mM) for 24 h and then stimulated with 50 ng/ml PDGF-BB. The cells were trypsinized and counted using hemocytometer after 24 h.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:42:16 GMT 2025` Edited by `admin` on `Mon Mar 31 22:42:16 GMT 2025`
Record UNII	27KIC0Q2VA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CORYNOXEINE

Common Name

English

.DELTA.18-RHYNCHOPHYLLINE

Preferred Name

English

SPIRO(3H-INDOLE-3,1'(5'H)-INDOLIZINE)-7'-ACETIC ACID, 6'-ETHENYL-1,2,2',3',6',7',8',8'A-OCTAHYDRO-.ALPHA.-(METHOXYMETHYLENE)-2-OXO-, METHYL ESTER, (.ALPHA.E,1'R,6'R,7'S,8'AS)-

Systematic Name

English

CORYNOXEIN

Common Name

English

CORYNOXAN-16-CARBOXYLIC ACID, 16,17,18,19-TETRADEHYDRO-17-METHOXY-2-OXO-, METHYL ESTER, (7.BETA.,16E,20.ALPHA.)-

Common Name

English

.DELTA.18-RHYNCOPHYLLINE

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID001318311